Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 3:23969873251341764.
doi: 10.1177/23969873251341764. Online ahead of print.

Assessment of patent foramen ovale closure in elderly patients with cryptogenic transient ischemic attack or stroke: Efficacy, safety, and potential age-related benefit

Chi-Sheng Wang  1 , Yu-Hsuan Wu  1 , Yun-Ching Fu  2   3 , Sheng-Ling Jan  4   5   6 , Ming-Chih Lin  3   7   8   9 , Chiann-Yi Hsu  10 , Po-Lin Chen  1   7   11
Affiliations

Assessment of patent foramen ovale closure in elderly patients with cryptogenic transient ischemic attack or stroke: Efficacy, safety, and potential age-related benefit

Chi-Sheng Wang et al. Eur Stroke J. .

Abstract

Introduction: The efficacy and safety of patent foramen ovale closure (PFOC) in cryptogenic stroke (CS) patients aged ⩾ 60 remain controversial. This study evaluates the efficacy and safety of PFOC in elderly (aged ⩾ 60) versus non-elderly (aged < 60) patients and examines potential age-related benefit.

Patients and methods: A hospital-based cohort study (January 2013-June 2023) compared the efficacy and safety between PFOC and non-PFOC groups in patient with CS or cryptogenic TIA. The primary efficacy outcome was recurrent ischemic stroke, and safety outcomes included procedure-related adverse events and periprocedural atrial fibrillation (AF). Subgroup analyses, including various age ranges, were performed for the elderly group.

Results: Among 239 patients (mean age 57.2 years), 120 were elderly. During a mean follow-up of 3.1 years, the PFOC group had significantly fewer recurrent ischemic stroke than the non-PFOC group (adjusted hazard ratio (AHR): 0.10, 95% CI: 0.03-0.29, p = 0.001). The risk reduction was similar in elderly (AHR: 0.11, p = 0.004) and non-elderly (AHR: 0.10, p = 0.005) patients (p for interaction = 0.337). Safety outcomes were comparable across age groups, including younger elderly (60-70) and older elderly (⩾70). No life-threatening complications occurred; one patient required additional intervention. Subgroup analysis indicated significant risk reduction for patients aged ⩾ 65 (AHR: 0.01, p = 0.012) but not for those aged 60-65 (AHR: 0.24, p = 0.071).

Discussion and conclusion: PFO closure is safe and effective in elderly patients with CS. Advanced age should not be a contraindication for PFOC, as older patients may potentially derive more significant benefits from the procedure.

Keywords: Elderly; patent foramen ovale; patent foramen ovale closure.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
Study flow diagram. AIS: acute ischemic stroke; TIA: transient ischemic attack; LAA: large artery atherosclerosis; SVO: small vessel occlusion; CS: cryptogenic stroke; PFOC: patent foramen ovale closure.
Figure 2.
Figure 2.
Subgroup analyses on the elderly group. PFOC: patent foramen ovale closure; AHR: adjusted hazard ratio; na: not applicable; HITS: high-intensity transient signals; RoPE: risk of paradoxical embolism.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Furlan AJ, Reisman M, Massaro J, et al.. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991–999. - PubMed
    1. Carroll JD, Saver JL, Thaler DE, et al.. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092–1100. - PubMed
    1. Saver JL, Carroll JD, Thaler DE, et al.. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377: 1022–1032. - PubMed
    1. Søndergaard L, Kasner SE, Rhodes JF, et al.. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377: 1033–1042. - PubMed
    1. Mas JL, Derumeaux G, Guillon B, et al.. Patent foramen ovale closure or anticoagulation versus antiplatelets after stroke. N Engl J Med 2017; 377: 1011–1021. - PubMed

LinkOut - more resources